Picture EBD Group Connector Personal Networking in Life Sciences 650x80
Document › Details

Zelluna Immunotherapy AS. (8/19/21). "Press Release: Exclusive License Agreement with the U.S. National Cancer Institute to Develop and Commercialize KK-LC-1 Targeting Allogeneic »Off-the-Shelf« TCR Based Natural Killer (TCR-NK) Cell Therapies". Oslo.

Organisations Organisation Zelluna Immunotherapy AS
  Organisation 2 National Cancer Institute (NCI) (US)
  Group United States (govt)
Products Product TCR engineering technology (T-cell receptor engineering technology)
  Product 2 allogeneic cell therapy product

Zelluna Immunotherapy, the company pioneering allogeneic “off the shelf” TCR based Natural Killer (TCR-NK) cells for the treatment of cancer, today announces an exclusive license agreement with the National Cancer Institute (NCI) of the National Institutes of Health, related to KK-LC-1 targeting allogeneic “off-the-shelf” TCR-NK cell therapies for the treatment of various solid cancers.

Under the agreement Zelluna will have exclusive rights from the NCI to use the well characterized KK-LC-1 TCR for the development and commercialization of a TCR-NK product. TCR-NK products are a novel and proprietary class of allogeneic cellular therapies that combine the inherent pan cancer killing mechanism, efficiency, and the allogeneic nature of NK cells with the targeting capabilities of TCRs. Arming NK cells with TCRs may unlock the potential to treat a wide range of currently untreatable cancers.

“This agreement is another important milestone for Zelluna. KK-LC-1 is an antigen with broad expression across solid cancers and very limited normal tissue distribution. The NCI KK-LC-1 TCR also comes with compelling preclinical validation making it an attractive candidate for us to exclusively initiate a TCR-NK program. With our recent announcements of in-licensing MAGE-A4 and VGLL1 TCRs, our pipeline is in a very strong position to deliver on our ambitions of testing first in class “off the shelf” TCR-NK products in solid cancer patients. “ said Luise Weigand, Head of Research at Zelluna.

“We continue to develop and expand our pipeline through in-licensing, collaborations and in-house TCR discovery. In a field where both TCRs and NKs continue to demonstrate huge potential, we are excited about bringing these two elements together in our proprietary TCR-NK platform. With a strong pipeline in place, we aim to deliver transformational “off the shelf” cell therapies to solid cancer patients with unmet medical need. “ said Anders Holm, COO / Head of BD at Zelluna.

About Zelluna Immunotherapy

Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumor specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable. For more information, please visit

Record changed: 2021-10-22


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

More documents for Zelluna Immunotherapy AS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

» top